Gail V Matthews

Summary

Affiliation: University of New South Wales
Country: Australia

Publications

  1. ncbi Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals
    Gail V Matthews
    National Centre in HIV Epidemiology and Clinical Research, UNSW, Sydney, Australia
    AIDS 23:1707-15. 2009
  2. ncbi A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand
    Gail V Matthews
    Viral Hepatitis Program, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Darlinghurst, Sydney, NSW, Australia
    Hepatology 48:1062-9. 2008
  3. ncbi Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C
    G V Matthews
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    Clin Infect Dis 48:650-8. 2009
  4. ncbi Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir
    Gail V Matthews
    HIV Immunology Infectious Diseases Unit, St Vincent s Hospital, Sydney, Australia
    Antivir Ther 12:119-22. 2007
  5. ncbi The management of HIV and hepatitis B coinfection
    Gail Matthews
    Viral Hepatitis Clinical Research Program, National Centre in HIV Epidemiology and Clinical Research, Sydney, New South Wales, Australia
    Curr Opin Infect Dis 20:16-21. 2007
  6. ncbi Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy
    Gail V Matthews
    National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, Australia
    AIDS 20:863-70. 2006
  7. ncbi HIV and hepatitis C coinfection
    Gail V Matthews
    Viral Hepatitis Program, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, New South Wales, Australia
    J Gastroenterol Hepatol 23:1000-8. 2008
  8. ncbi Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users
    Jason Grebely
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    J Hepatol 55:76-85. 2011
  9. ncbi Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection
    Jason Grebely
    National Centre in HIV Epidemiology and Clinical Research NCHECR, University of New South Wales UNSW, Sydney, Australia
    Hepatology 52:1216-24. 2010
  10. ncbi Effective treatment of injecting drug users with recently acquired hepatitis C virus infection
    Gregory J Dore
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    Gastroenterology 138:123-35.e1-2. 2010

Detail Information

Publications24

  1. ncbi Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals
    Gail V Matthews
    National Centre in HIV Epidemiology and Clinical Research, UNSW, Sydney, Australia
    AIDS 23:1707-15. 2009
    ..To determine if highly active antiretroviral therapy (HAART) with combination anti-hepatitis B virus (HBV) therapy compared to HAART with HBV monotherapy leads to greater HBV DNA suppression in an HIV/HBV coinfected cohort...
  2. ncbi A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand
    Gail V Matthews
    Viral Hepatitis Program, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Darlinghurst, Sydney, NSW, Australia
    Hepatology 48:1062-9. 2008
    ..This study confirms current treatment guidelines that recommend a TDF-based regimen as the treatment of choice for HIV/HBV coinfection, but does not demonstrate any advantage of HBV combination therapy in this short-term setting...
  3. ncbi Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C
    G V Matthews
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    Clin Infect Dis 48:650-8. 2009
    ..Enrollment is open to both human immunodeficiency virus (HIV)-infected and -uninfected individuals. The aim of this article was to evaluate characteristics and virological outcomes among HIV-infected individuals enrolled in ATAHC...
  4. ncbi Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir
    Gail V Matthews
    HIV Immunology Infectious Diseases Unit, St Vincent s Hospital, Sydney, Australia
    Antivir Ther 12:119-22. 2007
    ..The safety and efficacy of tenofovir in HIV/HBV cirrhosis has not been previously described...
  5. ncbi The management of HIV and hepatitis B coinfection
    Gail Matthews
    Viral Hepatitis Clinical Research Program, National Centre in HIV Epidemiology and Clinical Research, Sydney, New South Wales, Australia
    Curr Opin Infect Dis 20:16-21. 2007
    ..This review highlights the most important recent developments in the management of HIV and hepatitis B virus coinfection...
  6. ncbi Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy
    Gail V Matthews
    National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, Australia
    AIDS 20:863-70. 2006
    ..Little is known about the prevalence and pattern of hepatitis B virus (HBV) mutations in HIV/HBV co-infected individuals on long-term lamivudine (3TC) therapy...
  7. ncbi HIV and hepatitis C coinfection
    Gail V Matthews
    Viral Hepatitis Program, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, New South Wales, Australia
    J Gastroenterol Hepatol 23:1000-8. 2008
    ..New therapies, including HCV protease and polymerase inhibitors, are in development and may widen therapeutic options for HIV-HCV-coinfected individuals into the future...
  8. ncbi Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users
    Jason Grebely
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    J Hepatol 55:76-85. 2011
    ..We assessed 80/80 adherence (?80% of PEG-IFN doses, ?80% treatment), on-treatment adherence, and treatment completion in a study of treatment of recent HCV infection (ATAHC)...
  9. ncbi Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection
    Jason Grebely
    National Centre in HIV Epidemiology and Clinical Research NCHECR, University of New South Wales UNSW, Sydney, Australia
    Hepatology 52:1216-24. 2010
    ..Early therapeutic intervention could be recommended for individuals with unfavorable IL28B genotypes...
  10. ncbi Effective treatment of injecting drug users with recently acquired hepatitis C virus infection
    Gregory J Dore
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    Gastroenterology 138:123-35.e1-2. 2010
    ..We evaluated the efficacy of treatment of recent HCV infection in IDUs with acute and early chronic HCV...
  11. ncbi Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand
    Anchalee Avihingsanon
    The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia
    AIDS Res Ther 9:6. 2012
    ..abstract:..
  12. ncbi Increased intrahepatic apoptosis but reduced immune activation in HIV-HBV co-infected patients with advanced immunosuppression
    David M Iser
    Department of Medicine, University of Melbourne, St Vincent s Hospital, Melbourne, Australia
    AIDS 25:197-205. 2011
    ....
  13. ncbi Treatment of acute HCV infection
    Jason Grebely
    Viral Hepatitis Clinical Research Program, National Center in HIV Epidemiology and Clinical Research, University of New South Wales, Corner Boundary and West Streets, Darlinghurst, Sydney, NSW 2010, Australia
    Nat Rev Gastroenterol Hepatol 8:265-74. 2011
    ..This Review highlights current knowledge of the epidemiology, diagnosis, natural history and treatment of acute HCV infection, including proposed recommendations for the assessment and treatment of this infection...
  14. ncbi Future of hepatitis C therapy: development of direct-acting antivirals
    Gregory J Dore
    Viral Hepatitis Clinical Research Program, The Kirby Institute, The University of New South Wales, Australia
    Curr Opin HIV AIDS 6:508-13. 2011
    ....
  15. ncbi Prevalence, incidence and risk factors for hepatitis C in homosexual men: data from two cohorts of HIV-negative and HIV-positive men in Sydney, Australia
    Fengyi Jin
    National Centre in HIV Epidemiology and Clinical Research, Level 2, 376 Victoria Street, Darlinghurst, NSW 2010, Australia
    Sex Transm Infect 86:25-8. 2010
    ..We report prevalence, incidence and risk factors for HCV infection in community-based cohorts of HIV-negative and HIV-positive homosexual men in Sydney...
  16. ncbi Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study
    J Grebely
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia
    Drug Alcohol Depend 107:244-9. 2010
    ..Decisions about whether to initiate treatment for recently acquired HCV were mainly driven by clinical factors, rather than factors related to sociodemographics or injecting behaviors...
  17. ncbi Patterns and characteristics of hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian trial in acute hepatitis C
    G V Matthews
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Australia
    Clin Infect Dis 52:803-11. 2011
    ..The extent to which these separate epidemics overlap is unknown...
  18. ncbi Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa
    Gail V Matthews
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    AIDS 25:1727-35. 2011
    ..To examine HIV and hepatitis B virus (HBV)-related outcomes in HIV/HBV-coinfected participants in the PHIDISA II study by use of HBV-active vs. non-HBV-active antiretroviral therapy (ART)...
  19. ncbi Treatment for hepatitis C virus infection among current injection drug users in Australia
    Gail Matthews
    Viral Hepatitis Program, National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Darlinghurst, Australia
    Clin Infect Dis 40:S325-9. 2005
    ..Further studies are under way to examine outcomes of treatment for HCV among clients undergoing treatment for drug dependency who have chronic HCV infection and among current IDUs with acute and newly acquired HCV infection...
  20. ncbi Invasive amebiasis in men who have sex with men, Australia
    Damien Stark
    St Vincent s Hospital, Darlinghurst, New South Wales, Australia
    Emerg Infect Dis 14:1141-3. 2008
    ..e., Japan, Taiwan, and Republic of Korea. We report locally acquired invasive amebiasis in Sydney, Australia, exclusively in MSM...
  21. ncbi Response to Schmutz et al., 'Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection'
    Gail V Matthews
    AIDS 21:777-8. 2007
  22. ncbi Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals
    Peter A Revill
    Victorian Infectious Diseases Reference Laboratory, 10 Wreckyn Street, North Melbourne, Victoria 3051, Australia
    AIDS 21:1701-10. 2007
    ..To test this hypothesis, we have analysed genome-length sequences of HBV DNA from patients both prior to and during antiviral therapy...
  23. ncbi Further evidence of HCV sexual transmission among HIV-positive men who have sex with men: response to Danta et al
    Gail V Matthews
    AIDS 21:2112-3. 2007
  24. ncbi Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study
    Gail V Matthews
    Department of HIV Medicine, Chelsea Hospital, London, UK
    AIDS 16:53-61. 2002
    ..Clinical trial data is required to confirm these findings...